Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice.
The increasing global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the need for effective treatment strategies. This study investigated the combined effects of empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and curcumin (Cur), a natural polyphenol,...